The leading Belgian biotech company that develops, manufactures and commercializes molecular diagnostic tests that enable personalized medicine.

Multiplicom develops, manufactures and commercializes molecular diagnostic assays, p...
See More rovided as kits, which enable personalized medicine.

Founded in 2011 as a spin-off from the University of Antwerp and VIB, Multiplicom achieved end of 2012 its first CE-IVD-certification for the BRCA MASTR Dx assay for breast and ovarian cancer predisposition. It was the first company in Europe achieving a BRCA CE-IVD certification and it continues to develop and market quality controlled MPS-based assays. Therefore, it enables clinical laboratories to diagnose patients with a genetic disease or predisposition, steer cancer therapy, and identify congenital defects early in pregnancy.

The Multiplicom N.V. site, located at Galileïlaan 18 in Niel, Belgium, operates a Quality Management System to design, develop, manufacture and distribute CE-IVD products according to ISO 13485:2012.

On January 20, 2017, Agilent Technologies acquired Multiplicom N.V. With the completion of the acquisition, the Multiplicom team is a part of the Genomics Division within Agilent’s Diagnostics & Genomics Group.